Vivek Subbiah: The evolution of basket trials in cancer drug development

Vivek Subbiah shared on X/Twitter:

“Revolutionizing cancer drug development: Harnessing the potential of basket trials –

The landscape of cancer therapy has been transformed by advances in clinical next-generation sequencing, genomically targeted therapies and immunotherapies.

Basket trials have emerged as one of the efficient modern clinical trial designs that evaluate the efficacy of these therapies across multiple cancer types based on specific molecular alterations or biomarkers, irrespective of histology or anatomic location.

This review delves into the evolution of basket trials in cancer drug development, highlighting their potential prospects and current obstacles.”

For the article click here.
Source: Vivek Subbiah/X

Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research at the MD Anderson Cancer Network and a former Associate Professor in the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center.

Dr. Vivek Subbiah has served as the principal investigator in over 100 phase I/II trials and co-investigator in over 200 clinical trials and is known for his leadership in several first-in-human and practice-changing studies that directly led to approvals from the FDA, European Medicines Agency, and other agencies across the world. He is an expert in tumor agnostic precision oncology and leads the BRAF and RET tissue agnostic studies to FDA approval.